IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 4738 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  NAVIGATE Here 
    Next article
    Previous article
    Table of Contents

 RESOURCE Links
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed9831    
    Printed155    
    Emailed3    
    PDF Downloaded380    
    Comments [Add]    
    Cited by others 13    

Recommend this journal

 

 NET STUDY
Year : 2007  |  Volume : 73  |  Issue : 3  |  Page : 209-

Topical betamethasone for prevention of radiation dermatitis


1 Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Medical physics, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
3 Department of Dermatology, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
4 Department of Pharmacology, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence Address:
Shapour Omidvari
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.32755

Rights and Permissions

Background: Although acute radiation dermatitis (ARD) is a common side-effect of radiotherapy (RT), currently there is no general consensus about its prevention or treatment of choice. Aims: The purpose of this study was to investigate whether prophylactic use of topical betamethasone 0.1% can prevent ARD caused by chest wall irradiation. Methods: Fifty-one patients who underwent modified radical mastectomy for breast cancer and were going to receive RT, were randomly assigned to receive topical betamethasone 0.1%, petrolatum or none during RT. The frequency and severity of ARD (measured using Radiation Therapy Oncology Group acute radiation morbidity scoring criteria) were recorded at the end of each week during RT and two weeks after its completion. Clinical outcomes were analyzed by relevant statistical methods. Results: All patients developed some degree of ARD, the frequency and severity of which increased with time and reached the maximum at the end of the seventh week for all groups. Patients receiving betamethasone had less severe ARD than the other two groups throughout the course of the study, but this difference was significant only at the end of the third week (p =0.027). No significant difference was observed between the petrolatum and control arms. Conclusion: Prophylactic and ongoing use of topical betamethasone 0.1% during chest wall RT for breast cancer delays occurrence of ARD but does not prevent it. Petrolatum has no effect on the prevention of ARD in these patients.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow